Table 1 Clinical features of included patients
| Â | TCGA | GSE39582 | P value |
|---|---|---|---|
Number (n) | 428 | 556 | Â |
Death [n(%)] | 98(22.9) | 187(33.6) |  < 0.001 |
Total survival time (mean ± SD, month) | 29.8 ± 25.6 | 57.5 ± 38.3 |  < 0.001 |
Survival time for dead patients (month) | 23.3 ± 22.7 | 37.4 ± 28.9 |  < 0.001 |
Survival time for living patients (month) | 31.7 ± 26.1 | 67.6 ± 38.4 |  < 0.001 |
Age (mean ± SD, year) | 66.5 ± 13.0 | 66.7 ± 13.3 | 0.825 |
Male [(n)%] | 230(53.7) | 306(55.0) | 0.686 |
Stage 4 [n(%)] | 60(14.0) | 59(10.6) |  < 0.001 |
Stage 3 [n(%)] | 124(28.9) | 203(36.5) | Â |
Stage 2 [n(%)] | 163(38.1) | 258(46.4) | Â |
Stage 1 [n(%)] | 70(16.4) | 31(5.6) | Â |
Stage (NA) [n(%)] | 11(2.6) | 4(0.7) | Â |
AJCC PT (T4) [n(%)] | 51(11.9) | 117(21.0) |  < 0.001 |
AJCC PT (T3) [n(%)] | 294(68.7) | 360(64.7) | Â |
AJCC PT (T2) [n(%)] | 72(16.8) | 43(7.7) | Â |
AJCC PT (T1) [n(%)] | 11(2.6) | 12(2.2) | Â |
AJCC PT (NA) [n(%)] | 0 | 24(4.3) | Â |
AJCC PN (N2) [n(%)] | 76(17.8) | 104(18.7) |  < 0.001 |
AJCC PN (N1) [n(%)] | 103(24.1) | 131(23.6) | Â |
AJCC PN (N0) [n(%)] | 249(58.2) | 294(52.9) | Â |
AJCC PN (NA) [n(%)] | 0 | 27(4.9) | Â |
AJCC PM (M1) [n(%)] | 107(25.0) | 60(10.8) |  < 0.001 |
AJCC PM (M0) [n(%)] | 315(73.6) | 473(85.1) | Â |
AJCC PM (NA) [n(%)] | 6(1.4) | 23(4.1) | Â |
Lymphovascular invasion (yes/no/NA) | 148/237/43 | NA | Â |
Vascular invasion (yes/no/NA) | 89/281/58 | NA | Â |
Residual tumor (3/2/1/0/NA) | 23/21/4/307/73 | NA | Â |
Perineural invasion (yes/no/NA) | 45/126/257 | NA | Â |